Extended Platelet Parameters as a Means to Differentiate Immune Thrombocytopenia From Hypo-proliferative Thrombocytopenias.
| Status: | Recruiting |
|---|---|
| Conditions: | Blood Cancer, Blood Cancer, Infectious Disease, Anemia, Hematology |
| Therapuetic Areas: | Hematology, Immunology / Infectious Diseases, Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 4/21/2016 |
| Start Date: | October 2013 |
| End Date: | December 2016 |
| Contact: | Mala Varma, MD |
| Email: | Mvarma@chpnet.org |
| Phone: | 212 523 2180 |
To utilise extended platelet parameters in order to individuate Immune Thrombocytopenia
(ITP) from hypo-proliferative causes of thrombocytopenia.
To develop the clinical potential of the extended platelet parameters as they pertain to
distinguishing different causes of thrombocytopenia from one another.
To test the hypothesis that mean platelet component (MPC) and mean platelet mass (MPM) might
distinguish between thrombocytopenia related to bone marrow dysfunction and immune mediated
destruction of platelets.
(ITP) from hypo-proliferative causes of thrombocytopenia.
To develop the clinical potential of the extended platelet parameters as they pertain to
distinguishing different causes of thrombocytopenia from one another.
To test the hypothesis that mean platelet component (MPC) and mean platelet mass (MPM) might
distinguish between thrombocytopenia related to bone marrow dysfunction and immune mediated
destruction of platelets.
Patient to be registered at the Haematology-Oncology department Mount Sinai Roosevelt
Hospital.
Inclusion criteria are as follows:
All individuals age 18yrs and above capable of rendering consent Known ITP confirmed by
response to IVIG, glucocorticoids, or WinRho and exclusion of all other possible causes of
thrombocytopenia Confirmed aplastic anemia [as assessed through bone marrow trephine
biopsy]. Chemotherapy-induced thrombocytopenia assessed at time of predicted nadir.
Hospital.
Inclusion criteria are as follows:
All individuals age 18yrs and above capable of rendering consent Known ITP confirmed by
response to IVIG, glucocorticoids, or WinRho and exclusion of all other possible causes of
thrombocytopenia Confirmed aplastic anemia [as assessed through bone marrow trephine
biopsy]. Chemotherapy-induced thrombocytopenia assessed at time of predicted nadir.
Inclusion Criteria:
- All individuals age 18yrs and above capable of rendering consent
- Known ITP confirmed by response to intravenous immune globulin (IVIG),
glucocorticoids, or winRho and exclusion of all other possible causes of
thrombocytopenia
- Confirmed aplastic anemia [as assessed through bone marrow trephine biopsy]
- Chemotherapy induced thrombocytopenia assessed at time of predicted nadir.
Exclusion Criteria:
- Suspected multifactorial thrombocytopenias and thrombocytopenia due to hypersplenism
- Chronic active hepatitis
- Those infected with HIV
- Patients receiving concomitant radiotherapy
- Gravid females
- Congenital thrombocytopenias
We found this trial at
1
site
New York, New York 10019
Principal Investigator: Mala Varma, MD
Phone: 212-523-2180
Click here to add this to my saved trials
